RxDoctor Payments Data

Barry Kavanaugh, OD

Optometrist · West End, NCNPI 1124076856

Payments from drug & device makers

$1,572in general payments, 2019–2025

Across 29 payments — averaging $54.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$559
  • Coopervision Inc.$184
  • Tarsus Pharmaceuticals, Inc.$154
  • AbbVie$149
  • Bausch & Lomb Americas Inc.$139
  • Mallinckrodt Hospital Products Inc.$125
  • plus $262 from 5 others

What the payments were for

  • Food & beverage$1,572100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,572 in reported general payments places this provider in the 55th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$153,049
Medicare patients
642
Services billed
2,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost90$31,939
RestasisCyclosporine21$16,363
VyzultaLatanoprostene Bunod13$6,907
Alphagan PBrimonidine Tartrate13$5,071
Cyclosporine11$4,627
Latanoprost363$4,228
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol43$4,050
Loteprednol Etabonate12$1,616
Brimonidine Tartrate21$1,597
Timolol Maleate47$1,261
Tobramycin-DexamethasoneTobramycin/Dexamethasone19$961
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat36$817
ErythromycinErythromycin Base36$460
Ofloxacin17$259
Acyclovir15$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$149$53,373124 claims
Bausch & Lomb Americas Inc.Vyzulta$139$6,90713 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$65$1,61612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in West End

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →